Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target

MT Newswires Live

07/16

Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.

The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.

The Minder system is an implant placed under the scalp to continuously monitor brain waves.

"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting," said Epiminder CEO Rohan Hoare.

The company's shares gained over 1% in recent Thursday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651974654"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651974654\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651974654?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651974654","market":"nz","top_or_hot":-1,"title":"Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target","media":"MT Newswires Live","content":"<html><body><p> Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.</p><p>The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.</p><p>The Minder system is an implant placed under the scalp to continuously monitor brain waves.</p><p>\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.</p><p>The company's shares gained over 1% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEpiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-16 10:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.</p><p>The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.</p><p>The Minder system is an implant placed under the scalp to continuously monitor brain waves.</p><p>\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.</p><p>The company's shares gained over 1% in recent Thursday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651974654","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651974654","pubTimestamp":1784167702,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Epiminder  said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.The Minder system is an implant placed under the scalp to continuously monitor brain waves.\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.The company's shares gained over 1% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","EPI.AU":"Epiminder Limited"},"translate_title":"Epiminder 在癫痫研究中提前达到 50 名患者入组里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPI.AU":1},"content_text":"Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.The Minder system is an implant placed under the scalp to continuously monitor brain waves.\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.The company's shares gained over 1% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}